Cytokinetics executives said their first FDA-approved drug is off to a strong start as it goes up against its Bristol Myers Squibb rival in a type of heart disease.
February 25, 2026 03:17 PM EST
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug
Cytokinetics executives said their first FDA-approved drug is off to a strong start as it goes up against a Bristol Myers Squibb rival in a …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and…
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost…
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA,…
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
